Kala Pharmaceuticals Inc.
13F holders, Q4 2025 (December 31)3holders +1
1new positions
0sold out
$0.56avg. 13F price*
At the end of Q4 2025, 3 institutions reported holding Kala Pharmaceuticals Inc. in their 13F filings, up 1 from Q3 2025. 1 opened new positions and 0 sold out. The largest holders were Fortitude Family Office, LLC ($394), Cheviot Value Management, LLC ($89) and Parallel Advisors, LLC ($1).
- Company
- Kala Pharmaceuticals Inc.
- Filed as
- KALA BIO INC COM NEW (Q4 2025)
- CUSIP
- 483119103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $394 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 709 shares bought, net +709 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Fortitude Family Office, LLC | 0.00% | New | 709 | $394 |
| Cheviot Value Management, LLC | 0.00% | No change | 153 | $89 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is KALA PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Kala Pharmaceuticals Inc. the manager owns.